TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25415250
Drug: Antibiotics (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (500 mg metronidazole plus 375 mg amoxicillin three times per day for 7 days) during the first, non‐surgical phase of periodontal therapy (T1)
Study: 25415250
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during the first, non‐surgical phase of periodontal therapy (T1)
Study: 25415250
Drug: Antibiotics during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics during the second, surgical phase of periodontal therapy (T2)
Study: 25415250
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during the second, surgical phase of periodontal therapy (T2)
Study: 23498850
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg tablet every 6 months)
Study: 21255511
Drug: Manual titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual titration by respiratory therapist
Study: 18245541
Drug: E75 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E75 vaccine (HER2/neu 369-377) + granulocyte macrophage colony-stimulating factor, given intradermally to previously treated, disease-free NP breast cancer patients.
Study: 16476069
Drug: Mitogenic bovine
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitogenic bovine whey extract (2.5 mg/mL)
Study: 16476069
Drug: Mitogenic bovine
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitogenic bovine whey extract (10.0 mg/mL)
Study: 9792996
Drug: Gastrin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gastrin infusion at 5 pmol kg‐1 h
Study: 9792996
Drug: Gastrin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gastrin infusion at 15 pmol kg‐1 h
Study: 9792996
Drug: Low-dose gastrin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose gastrin stimulated acid output
Study: 9792996
Drug: High-dose gastrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose gastrin stimulated acid output
Study: 9792996
Drug: Plasma PP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma PP levels during gastrin‐17 infusion
Study: 3144329
Drug: Metoprolol 50
Normalized name: metoprolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 50 mg or 100 mg twice daily
Study: 3144329
Drug: Verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120 mg or 240 mg twice daily
Study: 30475967
Drug: Nut group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nut group (60 g of a mixture of nuts/d)
Study: 28112077
Drug: Dietary cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary cholesterol (600 mg/d)
Study: 28112077
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols (2 g/d)
Study: 16780670
Drug: Basic internal
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic internal medication (Control)
Study: 10654017
Drug: Oral metronidazole;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metronidazole; 20 courses (18 empiric)
Study: 10654017
Drug: Oral vancomycin;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vancomycin; 10 courses (8 empiric)
Study: 1420042
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous propofol infusion
Study: 1420042
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous midazolam infusion
Study: 1420042
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous sedation
Study: 2864258
Drug: Hydroxyzine 20
Normalized name: pentaerythritol/hydroxyzine 20 mg-10 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 20 mg
Study: 32044
Drug: Clemastine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine 3 mg
Study: 2864258
Drug: Azatadine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azatadine 3 mg
Study: 2864258
Drug: Compound score
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound score (Hydroxyzine)
Study: 30880909
Drug: Seawater spray
Normalized name: Sodium Chloride 2600 mg in 100 mL NASAL SPRAY [NasalAsalt All-Natural Seawater]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seawater spray (Quinton®) five times daily
Study: 25268516
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg once daily for a maximum of 28 days
Study: 22985805
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for a maximum of 28 days
Study: 25424809
Drug: MenC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenC vaccine
Study: 16298658
Drug: Daclizumab 1
Normalized name: daclizumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 1 mg/kg/dose every 14 days for 5 doses (Group I, n = 107)
Study: 16298658
Drug: Daclizumab 2
Normalized name: daclizumab 25 MG per 5 ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 2 mg/kg/dose every 14 days for 2 doses (Group II, n = 113)
Study: 16298658
Drug: No antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibody induction (Group III, n = 78)
Study: 16298658
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups received tacrolimus (TAC), mycophenolate mofetil (MMF), and steroids
Study: 7767531
Drug: 4% lidocaine
Normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% lidocaine (5 cc)
Study: 7767531
Drug: Saline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (5 cc)
Study: 2272043
Drug: 3.0 g/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g/m2 AraC
Study: 2272043
Drug: 1.0 g/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g/m2 AraC
Study: 31400337
Drug: Vasopressin infusion
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin infusion for 24 hours after cardiopulmonary bypass
Study: 19103732
Drug: High-dose epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose epirubicin with cyclophosphamide (HEC)
Study: 19103732
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose of epirubicin, 60 mg/m(2) (EC)
Study: 19103732
Drug: Classical oral
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical oral cyclophosphamide, methotrexate, and fluorouracil (CMF)
Study: 12771114
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin (0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate, n = 8506)
Study: 10720165
Drug: Walnut diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut diet (43-57 g/d, 12.5% of energy from walnuts)
Study: 9352475
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g inositol
Study: 24627301
Drug: Zolpidem 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 40 mg
Study: 3985604
Drug: Tinidazole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (50 mg/kg of body weight to a maximum of 2 g)
Study: 3985604
Drug: Metronidazole (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (60 mg/kg of body weight to a maximum of 2.4 g)
Study: 3985604
Drug: Metronidazole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (50 mg/kg of body weight to a maximum of 2 g daily for 3 days)
Study: 30907345
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment (psychological and behavioral intervention + biofeedback)
Study: 30276476
Drug: Curcumin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (500 mg/day for 3 days)
Study: 21935584
Drug: MMRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV vaccine (GlaxoSmithKline Biologicals), 2 doses 42-56 days apart, N=371
Study: 21935584
Drug: MMR +
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR + V (Priorix™ and Varilrix™), 1 dose each administered simultaneously, followed by another MMR vaccination 42-56 days later, N=123
Study: 17604960
Drug: Low-dose anthracycline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose anthracycline treatment
Study: 16139696
Drug: Mandibular two‐implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular two‐implant overdentures (IOD; n=54)
Study: 12474023
Drug: Atorvastatin Na+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin Na+
Study: 30369433
Drug: 0.5-mg/kg ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-mg/kg ketamine
Study: 30369433
Drug: 0.2-mg/kg ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2-mg/kg ketamine
Study: 25451556
Drug: n‐3 PUFAs/LC
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 PUFAs/LC n‐3 PUFAs intake (fish/shellfish, fish oil supplements, perilla oils) for 24 months
Study: 21455075
Drug: i-gel device
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel device
Study: 18704870
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy module (EG 2)
Study: 12474114
Drug: Ayahuasca (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayahuasca (0.6 mg and 0.85 mg DMT/kg body weight)
Study: 10095919
Drug: Oral antibacterial
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibacterial drugs for uncomplicated pneumonia
Study: 8861134
Drug: High dietary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dietary magnesium (315 mg/d)
Study: 8861134
Drug: Low dietary
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dietary magnesium (115 mg/d)
Study: 8861134
Drug: High dietary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dietary boron (3.23 mg/d)
Study: 8861134
Drug: Low dietary
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dietary boron (0.23 mg/d)
Study: 2101950
Drug: Salbutamol via
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol via metered-dose inhaler (MDI)
Study: 7380993
Drug: Oral Metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Metoclopramide (10 mg)
Study: 7380993
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg) during dopamine infusion
Study: 29807495
Drug: Latina Breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latina Breast Cancer Survivorship Intervention (telephone-based, 3 education sessions weekly, 6 support calls)
Study: 23248895
Drug: Multi-directional power
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-directional power toothbrush (Oral-B Professional Deep Sweep TRICLEAN 1000)
Study: 18543584
Drug: Dexibuprofen tablets
Normalized name: Ibuprofen
DrugBank: Dexibuprofen (DB09213)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexibuprofen tablets (400 mg)
Study: 18543584
Drug: Racemic ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Racemic ibuprofen tablets (400 mg)
Study: 16633363
Drug: Immediate consolidation
Normalized name: BAG,LEG LARGE CONSOLIDATED #0932
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate consolidation with high-dose chemotherapy and hematopoietic support
Study: 12941199
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies (C225 and ABX‐EGF) and tyrosine kinase inhibitors (ZD1839 and OSI‐774)
Study: 12941199
Drug: Inhibitors of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitors of farnesyl transferase (R115777 and SCH66336)
Study: 12941199
Drug: Inhibitors of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitors of vascular growth factor receptor (bevacizumab and PTK787)
Study: 12941199
Drug: Cyclooxygenase‐2 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclooxygenase‐2 inhibitors in colorectal cancer and STI571 in GI stromal tumors
Study: 12941199
Drug: Novel agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel agents administered alone or in combination with standard therapies
Study: 10532418
Drug: Ki‐67 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ki‐67 antibody for cell proliferative activity
Study: 1953228
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg twice a day for 8 weeks
Study: 1953228
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg twice a day for an additional 8 weeks
Study: 27914297
Drug: Vildagliptin add-on
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin add-on therapy
Study: 27914297
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy without DPP-4 inhibitors
Study: 25061034
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) and stretching exercise
Study: 25061034
Drug: Intramuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular electrical stimulation (IMS) and stretching exercise
Study: 23093040
Drug: Adverse drug
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse drug events (ADEs)
Study: 23093040
Drug: Other drug-related
Normalized name: OTHER DRUGS FOR ACID RELATED DISORDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drug-related problems (DRPs)
Study: 23093040
Drug: Problems with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problems with administration and dosing of medicine
Study: 18392557
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy with careful monitoring of INR
Study: 10155208
Drug: Heparin-coated coronary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated coronary stents
Study: 3038423
Drug: Enalapril 2.5
Normalized name: enalapril 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 2.5 to 10 mg once daily
Study: 27069153
Drug: BCG instillation
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG instillation (one-third dose, three weekly instillations every 6 months for 3 years)
Study: 27069153
Drug: BCG instillation
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG instillation (two weekly instillations every 3 months for 3 years)
Study: 23733528
Drug: Medication diary-book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication diary-book
Study: 23733528
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard parental education program and donated chemotherapy)
Study: 20416246
Drug: Enema administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enema administered before surgery
Study: 20416246
Drug: No enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: No enema administered (Control)
Study: 16548361
Drug: Yigong Zhixue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yigong Zhixue Oral Liquid, taken orally
Study: 16548361
Drug: Yigong Zhixue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yigong Zhixue Oral Liquid
Study: 2901815
Drug: Oral slow
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral slow release morphine 30 mg
Study: 28776345
Drug: Daytime solifenacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daytime solifenacin dosing
Study: 28776345
Drug: Nighttime solifenacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nighttime solifenacin dosing
Study: 12452235
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg epidural morphine
Study: 23921652
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg epidural morphine
Study: 18371466
Drug: 12-month dual
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12-month dual antiplatelet therapy
Study: 14664687
Drug: Treatment effects
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effects analysis
Study: 8751803
Drug: TAM (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAM (30 mg/day) and MPA (800 mg/day)
Study: 8751803
Drug: TAM (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAM (30 mg/day)
Study: 8751803
Drug: MPA (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA (800 mg/day)
Study: 30452719
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (mainly UFT)
Study: 10441825
Drug: PLIF with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLIF with Moss-Miami implants
Study: 2126002
Drug: Multi-drug combination
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-drug combination chemotherapy (VMCP)
Study: 31093941
Drug: Clinical pharmacist
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacist led medication review using the RASP list
Study: 21957592
Drug: Pain syndrome
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain syndrome therapy (Duloxetin and Gabapentin)
Study: 19620930
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg/kg body weight + 0.125 g/kg carbohydrate)
Study: 19620930
Drug: Placebo (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.125 g/kg carbohydrate)
Study: 17225141
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg urapidil
Study: 2969740
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg doxazosin
Study: 15072419
Drug: Intratympanic buffer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratympanic buffer solution (placebo)
Study: 9060016
Drug: Phentolamine (alpha‐adrenoreceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine (alpha‐adrenoreceptor antagonist)
Study: 17917935
Drug: 5% imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% imiquimod cream, 8 weeks of treatment with once‐daily dosing for alternate weeks (R1)
Study: 17917935
Drug: 5% imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% imiquimod cream, 5 weeks of once‐daily dosing with a 1‐week interval (R2)
Study: 17313005
Drug: Diltiazem (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (oral administration)
Study: 15297112
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral carbohydrate treatment (12.5%, 800 + 400 ml, n = 8)
Study: 8157045
Drug: Terbutaline slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline slow-release 7.5 mg
Study: 31657168
Drug: PGLA thread-embedding
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGLA thread-embedding therapy combined with rehabilitation training
Study: 28343601
Drug: RG7652 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7652 (1 of 5 doses)
Study: 26489661
Drug: specialised Helping
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: specialised Helping Young People Early service model plus up to 16 sessions of individual cognitive analytic therapy
Study: 24188276
Drug: Comprehensive traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comprehensive traditional Chinese medicine rehabilitation protocol
Study: 19422296
Drug: AdoMet (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: AdoMet (800 mg per day) for 4 weeks
Study: 11731184
Drug: Calcitonin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin and 1 alpha-hydroxycholecalciferol combination
Study: 9095326
Drug: Combination regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimen
Study: 11731184
Drug: Calcitonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin treatment
Study: 9789699
Drug: Procainamide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procainamide (100 mg i.v. bolus every 5 min up to 1 g)
Study: 9789699
Drug: Propafenone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (2 mg/kg body weight i.v. over 30 min)
Study: 2585215
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 (5 mg intramuscularly)
Study: 793777
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg amitriptyline as 3 daytime doses
Study: 793777
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg amitriptyline as a single dose at bedtime
Study: 31105976
Drug: Continuing prestroke
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing prestroke antihypertensives
Study: 31105976
Drug: Stopping prestroke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping prestroke antihypertensives
Study: 28809637
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment using plate osteosynthesis (LCP Distal Ulna Plate) for proximal third ulnar styloid process fractures, ulnar head fractures, and subcapital fractures.
Study: 28809637
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for tip fractures of ulnar styloid process.
Study: 28809637
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for ulnar base fractures.